Altimmune Announces Oral Presentation of Pemvidutide Clinical Data in Treatment of NAFLD at Upcoming EASL International Liver Congress™ 2023
15 Junho 2023 - 8:30AM
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical
company, today announced that Dr. Stephen A. Harrison, Medical
Director, Pinnacle Clinical Research and Adjunct Professor of
Medicine, Oxford University, will present the results of its
24-week clinical trial of pemvidutide in the treatment of
non-alcoholic fatty liver disease (NAFLD) in an oral presentation
at the EASL International Liver Congress™ 2023 in Vienna, Austria.
Pemvidutide is a novel, investigational, peptide-based
GLP-1/glucagon dual receptor agonist in development for the
treatment of obesity and non-alcohol steatohepatitis (NASH).
Details for the oral presentation are as
follows:
Title: |
Pemvidutide, a GLP-1/Glucagon Dual Receptor Agonist, Significantly
Reduces Liver Fat, Fibro-inflammation, and Body Weight in Patients
with Non-alcoholic Fatty Liver Disease: a 24-week Multicenter,
Randomized, Double-blind, Placebo-controlled Trial (Presentation ID
OS-063) |
Presenter: |
Stephen A. Harrison, M.D., Medical Director, Pinnacle Clinical
Research and Adjunct Professor of Medicine, Oxford University |
Date/Time: |
Friday, June 23, 2023, at 8:30 am CEST |
Best of EASL Summary Slide
Deck
Dr. Harrison’s presentation was selected for the
Best of EASL Summary Slides, a compendium highlighting the most
noteworthy contributions to the 2023 EASL program. A copy of the
presentation will be accessible on the Events section of the
Altimmune website.
NASH KOL and Investor
Reception
Altimmune will host a reception in Vienna for
NASH KOLs and investors on Thursday, June 22 at 6:30 PM CEST.
Please click here if you are interested in attending the reception
and to receive additional details.
About Altimmune
Altimmune is a clinical-stage biopharmaceutical
company focused on developing innovative next-generation
therapeutics for the treatment of patients with liver diseases and
obesity. The Company’s lead product candidate, pemvidutide, is a
GLP-1/glucagon dual receptor agonist that is being developed for
the treatment of obesity and NASH. In addition, Altimmune is
developing HepTcell™, an immunotherapeutic designed to achieve a
functional cure for chronic hepatitis B. For more information,
please visit www.altimmune.com.
Follow @Altimmune, Inc. on
LinkedInFollow @AltimmuneInc on
Twitter
Investor & Media Contacts:
Richard EisenstadtChief Financial OfficerPhone:
240-654-1450reisenstadt@altimmune.com
Altimmune (NASDAQ:ALT)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Altimmune (NASDAQ:ALT)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024